Document:

EX-10.1

SEPARATION AGREEMENT

THIS SEPARATION AGREEMENT (“Separation Agreement”) sets forth the voluntary agreement
reached between Robert C. Strauss (“Executive”) and Noven Pharmaceuticals, Inc. (“Noven”), a
Delaware corporation (Executive and Noven, collectively, referred to as “Parties”). The “Effective
Date” of this Separation Agreement shall be the eighth day following the signing of this Separation
Agreement by Executive.

WHEREAS, Executive and Noven entered into an Amended and Restated Employment Agreement dated
November 5, 2003 (“Employment Agreement”), which Employment Agreement expired on December 31, 2007;

WHEREAS, Executive shall retire contemporaneously with the expiration of the Employment
Agreement; and

WHEREAS, the Parties desire to end the employment relationship on the terms and conditions set
forth in this Separation Agreement.

NOW THEREFORE, in order to provide for an amicable end to the employment relationship and to
ensure resolution of any potential disputes between them, Noven and Executive enter into this
Separation Agreement and agree to the following:

1. Executive’s employment with Noven ended December 31, 2007, contemporaneously with the
expiration of the Employment Agreement. The Employment Agreement is of no further force or effect
and all rights and obligations of the Parties stated in or provided for by the Employment Agreement
terminated. Executive shall not execute this Separation Agreement prior to December 31, 2007.

2. Executive’s position as Chief Executive Officer and President and Executive’s position as a
Director of Noven and as Chairman of the Board of Directors of Noven terminated effective December
31, 2007.

3. In exchange for the promises Executive makes in this Separation Agreement, Noven will:

	 	a.	 	Pay Executive an amount equal to $1,080,597, minus applicable taxes and
withholding (“Separation Pay”). The Separation Pay will be paid in lump sum on or
before March 15, 2008.

	 	b.	 	Pay Executive an amount under the 2007 Management Incentive Plan (“MIP
Award”). The amount of the MIP Award shall be based on Noven’s financial
performance in 2007 against the Management Incentive Plan’s performance matrix,
subject to and consistent with any adjustments made by Noven for its executive
officers. The MIP Award, minus applicable taxes and withholding, shall be paid at
the same time and in the same manner as paid to the Noven’s executives officers.

	 	c.	 	Grant to Executive on the Effective Date of this Separation Agreement,
pursuant to the Noven Pharmaceuticals, Inc., 1999 Long-Term Incentive Plan
(“Plan”), restricted stock units (“RSUs”) for 50,000 shares (the “Shares”) of
Noven’s Common Stock, par value $0.0001 per share (the “Common Stock”), in
accordance with the terms and conditions of the Award Agreement attached hereto as
Exhibit A. So long as Executive does not violate the covenants provided for by
Sections 12 and 14 of this Separation Agreement, Executive shall vest in the RSUs
two (2) years after the Effective Date of this Separation Agreement (“Vesting
Date”). In the event Executive violates the covenants provided for by Sections 12
and 14 of this Separation Agreement at any time prior to the Vesting Date, the RSUs
will immediately be forfeited and any right to receive the Shares pursuant to the
RSU shall immediately terminate. Within ten (10) business days after the Vesting
Date, except as otherwise provided below, Noven shall deliver to Executive (or his
estate) the Shares corresponding to the vested RSUs (on a one-for-one basis of one
Share for each RSU). The number of Shares to be delivered in connection with the
RSU grant shall be subject to adjustment as provided in the Plan. Upon delivery of
the Shares to Executive, Executive shall deliver to Noven such amount of money, or
instruct Noven to withhold a portion of such Shares, as required for Noven to
satisfy its withholding obligation under applicable tax laws or regulations.
Except as expressly provided in this Separation Agreement, Executive shall not have
any rights with respect to any Shares subject to the RSUs until the Shares have
been delivered to Executive. The RSUs are not transferable otherwise than by will
or under applicable laws of descent and distribution.

	 	d.	 	Allow each of Executive’s outstanding vested stock options and vested
stock appreciation rights in Noven to be exercised on or before the earlier of
December 31, 2009; provided, however, that no stock option or stock appreciation
right may be exercised after the expiration of its term as provided for in the
applicable award agreement. All stock options and stock appreciation rights not
vested as of December 31, 2007, shall be forfeited and terminated. Except as
provided in this paragraph, each stock option and stock appreciation right must be
exercised in accordance with its award agreement and the applicable plan.

	 	e.	 	Pay Executive an amount equal to his unused vacation time which had
accrued as of December 31, 2007, minus applicable taxes and withholding (“Vacation
Pay”). This Vacation Pay will be paid as a lump sum, minus applicable taxes and
withholding, within fifteen (15) business days after the Effective Date of this
Separation Agreement.

4. The above payments and benefits referred to in Section 3 constitute the entire separation
package being offered to Executive. Executive shall not be entitled to receive any other payments,
salary, compensation, bonuses, commissions, incentives, benefits, perquisites, or other monies or
remuneration from Noven or any of the Releasees (as defined below).

5. Executive acknowledges and agrees that the payments and benefits he is receiving in
Sections 3a. and 3c. constitute adequate and sufficient consideration for the promises and
obligations arising under the terms of this Separation Agreement and agrees that such payments and
benefits constitute consideration to which he would not otherwise be entitled but for his execution
of this Separation Agreement. Executive acknowledges he has entered into this Separation Agreement
voluntarily and knowingly.

6. Executive agrees that he is not entitled to reemployment with Noven, and that he will not
seek employment with Noven or any of the Releasees in any capacity at any time in the future.
Executive agrees that this forbearance to seek future employment is purely contractual and is in no
way involuntary, discriminatory or retaliatory.

7. Subject to Sections 8 and 21, Executive waives and fully releases and forever discharges
Noven and any and all of its parent companies, affiliates, holding companies, subsidiaries or other
related entitles, and any and all of their respective past and present officers, directors,
shareholders, attorneys, agents, insurers, employees, predecessors, successors, and assigns, both
in their representative and individual capacities (collectively referred to with Noven as
“Releasees”), from any and all claims, rights, and causes of action, in law or in equity, of any
kind whatsoever, which Executive has or may have against any or all of the Releasees as of the date
Executive signs this Separation Agreement, whether such claims, rights, or causes of action are now
known or are later discovered. Subject to Sections 8 and 21, Executive agrees that this waiver and
release shall be construed as broadly as possible and shall include, without limitation, any (1)
contractual or other claims of employment or payment Executive may have against any or all of the
Releasees; (2) claims, if any, arising out of or in connection with the initiation, separation, or
existence of Executive’s employment relationship with any or all of the Releasees; (3) claims, if
any, regarding accrued leave, vacation, bonuses, back pay, overtime, commissions, or any other form
of benefits connected with Executive’s employment with any or all of the Releasees; and (4) claims,
if any, arising under the Age Discrimination in Employment Act or the Older Workers Benefit
Protection Act and any other federal, state, or local statute or regulation, and any allegation for
costs, fees or other expenses including attorney’s fees.

8. The waiver contained in the above Section does not affect Executive’s entitlement to (i)
Executive’s rights under this agreement, and (ii) any vested benefits under any Noven employee
pension or welfare benefit plans. Executive’s entitlement to any vested pension or welfare
benefits will continue to be governed by the terms of those plans.

9. Executive shall not sue any or all of the Releasees, except in the event that Noven
breaches this Separation Agreement or where Executive challenges the validity of this Separation
Agreement under the Age Discrimination in Employment Act/Older Workers Benefit Protection Act.
Executive retains the right to file a charge with, or participate in any investigation or
proceeding before any governmental agency such as the Equal Employment Opportunity Commission. If
Executive does file such a charge, however, this Separation Agreement prevents Executive from
recovering any relief whatsoever, including any award of money, as a result of such charge or
future action/proceeding based on such charge.

10. Executive acknowledges that Executive has been paid all salary and bonuses and any and all
other pay and incentives due to Executive, through the date hereof; that Executive has been
provided with all leave (including leave under the Family and Medical Leave Act) to which Executive
may have been entitled, if any; and that Executive has not suffered any workplace illness or injury
other than any injury or illness of which Executive has already advised Noven, if any.

11. Executive shall not take any action or make any comments which would reasonably be
expected to embarrass, harass or adversely affect Noven or any of the Releasees, or their
respective business operations, practices or services. In particular, Executive agrees not to
contact the press or media, Noven’s or any of the Releasees’ associates, attorneys, staff, or
clients, or any entity that has a business relationship with Noven or any of the Releasees, in
order to disparage, directly or indirectly, the good reputation or business practices of Noven or
any of the Releasees, or any of their current or former shareholders, attorneys, officers,
directors, managers, or employees.

12. Executive acknowledges that the provisions of this Section are reasonable and necessary
for the protection of Noven’s legitimate business interests.

	 	a.	 	Executive agrees that for a period of twenty-four (24) months following
the Effective Date of this Agreement (“Restricted Period”), Executive will not,
directly or indirectly (in any capacity, on Executive’s own behalf or on behalf of
any other person or entity):

	 	i.	 	Anywhere in the World, own an interest in any
business, including but not limited to, an individual proprietorship,
partnership, corporation, joint stock company, joint venture, limited
liability company, trust or other form of business entity, or
unincorporated organization (except for an ownership interest not
exceeding five percent (5%) of a publicly-traded entity), that is engaged
in any business that is of the type or character of business in which
Noven has been engaged at any time during Executive’s employment by
Noven;

	 	ii.	 	Anywhere in the World, as an individual proprietor,
principal, partner, shareholder, joint venturer, member, trustee,
officer, director, consultant, broker, employee, agent, trustee,
independent contractor, or in any manner whatsoever, perform any work for
or provide any services to or receive any remuneration from any person or
entity that is engaged in any business that is of the type or character
of business in which Noven has been engaged at any time during
Executive’s employment by Noven;

	 	iii.	 	Divert or attempt to divert from the Noven or
otherwise interfere with any business relationship which exists/existed
between the Noven and any specific prospective or existing client of the
Noven; and/or

	 	iv.	 	Hire or engage any Noven employee or contractor to
enter into an employment or business relationship with any other person
or entity or recruit, solicit or otherwise induce any Noven employee or
contractor to terminate his/her employment or engagement with the Noven.
This covenant applies as to any employee or contractor who, at the time
of the recruitment/hire, is currently employed or engaged with the Noven
or who was employed or engaged with the Noven at any time during the six
month period preceding the date of the attempted employment, recruitment,
or solicitation.

	 	b.	 	It is the intention of the Parties that this Section be enforceable to
the fullest extent permissible. Accordingly, Executive agrees that in the event
that any restriction stated in this Section, or any portion thereof, shall be
declared or held to be invalid or unenforceable by a court of competent
jurisdiction, then such restriction shall be amended or modified, as necessary, to
render it valid and enforceable. Further, if Executive violates any restriction
stated in this Section, such restriction shall remain in full force and effect
beyond the expiration of its twenty-four (24) month term(s), such that Noven
receives the full benefit of its bargain.

	 	c.	 	If Noven reasonably and in good faith determines that Executive has
breached or has threatened to breach any or all of the restrictions provided for by
this Section or Section 14: (i) Executively shall be immediately deemed to have
forfeited the RSUs otherwise granted under Section 3(c) of this Separation
Agreement and any right of Executive to receive Shares pursuant to the RSU grant
shall terminate; and (iii) Noven shall be relieved any further obligations under
Section 3(c) of this Separation Agreement.

	 	d.	 	Executive further agrees that a breach of this Section or Section 14
would result in irreparable and continuing damage to Noven. Accordingly, in the
event of a breach or threatened breach by Executive, Noven shall be entitled to
pursue immediately any and all remedies it may have against Executive in a court of
competent jurisdiction by specific performance, injunction, or such other remedies
and relief as may be available. Executive’s obligations under this Section 12
are independent of any obligation of Noven. The existence of any other claim
or cause of action by Executive, including but not limited to any other claim or
cause of action under this Agreement, does not constitute a defense to the
enforcement by Noven of the covenants contained in this Section or Section 14.

13. Executive agrees that prior to the commencement of any employment or consulting
relationship with any person or entity, Executive will advise the person or entity of the
restrictive covenant terms contained in this Separation Agreement.

14. Executive agrees that Noven provided him with access to certain confidential and
proprietary business information during his employment with Noven.

	 	a.	 	Executive acknowledges that Noven has a legitimate business interest in
preventing disclosure and dissemination of its Confidential Information (as defined
below). Accordingly, Executive agrees that all Confidential Information (i) is the
sole and exclusive property of Noven, (ii) will not be used by Executive for any
reason or purpose and (iii) will not be disclosed by Executive in whole or in part
to any person or entity. For the purposes of this Agreement, “Confidential
Information” means and includes all information, data and knowledge in any way
regarding or relating to Noven or, whether provided to or obtained by Executive,
including, without limitation: all Trade Secrets (as defined by applicable law);
Work Product (as defined below); algorithms, computer programs, methods, models,
software (including both source code and object code) and related documentation;
computer, network and telephony structures, schematics and designs; information
security information, processes and designs; sales and marketing information and
plans; business plans, ideas and methods; financial information; pricing
information and policies; procedures; research; business practices; know-how;
employee information; customer-related and supplier-related information (including,
without limitation, customer lists, client lists, customer contracts, supplier
lists, supplier contracts, terms and conditions, billing and payment information
and e-mail lists); training materials and techniques; internal industry forecasts;
product development, research, designs, concepts and ideas; pricing histories;
distribution information; and any information or material of third parties that
Noven is required to keep confidential. “Confidential Information” does not
include information that has previously been or is hereafter made public, without
breach of a confidential relationship, by an authorized representative of Noven.

	 	b.	 	Executive further assigns and transfers to Noven all of Executive’s
right, title and interest in and to any and all Proprietary Information, whether or
not patentable or registrable under copyright or similar statutes, made or
conceived or reduced to practice or learned by Executive, either alone or jointly
with others during a period in which Executive was employed by or serving as a
Executive to Noven. The term “Proprietary Information” shall include all ideas,
inventions, trademarks, service marks, trade dress, discoveries, designs (whether
ornamental or otherwise), writings, documents, presentations, audio or video
recordings, know-how, technical information, technology, algorithms, computer
programs, software or code (both source and object) and related documentation of
any kind, and all other works of authorship of any type or kind whether in written,
printed, verbal, electronic or other form (including, but not limited to, any
useful process, method, formula, technique, or computer program, as well as
improvements thereto), which were prepared, created, conceived, authored or
produced in whole or in part by the Executive, whether or not any such item or any
portion thereof is patentable, copyrightable, registered as a trademark or service
mark, or susceptible to other forms of intellectual property protection).
Inventions assigned to Noven, or to a third party as directed by Noven, are
referred to as “Company Inventions.”

	 	c.	 	Executive acknowledges that all original works of authorship which were
made by Executive (solely or jointly with others) while Executive was employed by
or serving as an Executive to Noven and which are protectible by copyright
(collectively “Works”) are “works made for hire,” pursuant to United States
Copyright Act (17 U.S.C. Section 101). In the event any such Works shall be deemed
not to be a work made for hire, Executive hereby sells, assigns, and transfers to
Noven, its successors, and assigns, all right, title, and interest in and to such
Works, in the United States and throughout the world, forever, including any and
all copyright terms, and all extension terms of copyright, for all uses and
purposes whether now known or hereafter created, free from payment of any royalty
or further compensation. Upon request of Noven, Executive shall take such further
actions, including execution and delivery of instruments of conveyance, that Noven
may reasonably deem necessary or desirable to accomplish or evidence more further
any transfer of right, title, or interest necessary to fulfill the intent of this
Agreement.

	 	d.	 	Executive will, upon Noven’s request and at Noven’s expense, assist
Noven in every proper way to obtain, and from time to time enforce, United States
and foreign Proprietary Information relating to Company Inventions in any and all
countries. To that end Executive will execute, verify and deliver such documents
and perform such other acts (including appearances as a witness) as Noven may
reasonably request for use in applying for, obtaining, perfecting, evidencing,
sustaining and enforcing such Proprietary Information and the assignment thereof.
In addition, Executive will execute, verify and deliver assignments of such
Proprietary Information to Noven or its designee. Executive hereby waives and
quitclaims to Noven any and all claims, of any nature whatsoever, which Executive
now or may hereafter have for infringement of any Proprietary Information assigned
hereunder to Noven.

15. Executive agrees that all records, files, plans, documents, software, reports, research,
and policies and procedures relating to the business of Noven that Executive prepared, used or came
into contact with shall be and shall remain the sole property of Noven and shall not be copied
without written permission from Noven. Executive shall not remove and shall return any and all
property belonging to Noven, including but not limited to all files, lists, records, computer
software or records or any other information relating to Noven no later than the Effective Date.

16. Executive will, prior to signing this Separation Agreement, disclose to Noven any and all
matters, information, or concerns of any type whatsoever of which Executive is aware regarding
Noven’s actions, policies, practices, and/or procedures, which Executive believes constitute
non-compliance with law, regulatory or safety rules, or other guidelines. All such disclosures
shall be in writing and attached to and made a part of this Separation Agreement. In addition, if
no such writing is attached to this Separation Agreement, Executive’s signature on this Separation
Agreement evidences the fact that Executive is not aware of any such matter, information, or
concern which could have, or should have, been disclosed, but which has not been disclosed.

17. In the event of a breach by Executive of any provision of this Separation Agreement, Noven
shall be entitled to pursue immediately any and all remedies it may have against Executive in a
court of competent jurisdiction by specific performance, injunction, or such other remedies and
relief as may be available. It is agreed that in the event of any litigation or proceeding under
this Separation Agreement (other than an action challenging the validity of this Separation
Agreement under the Older Workers Benefit Protection Act), including with regard to the enforcement
of the restrictive covenants set forth in this Separation Agreement, the prevailing party shall be
entitled to all costs and expenses incurred in such litigation or proceeding, including reasonable
attorney’s fees from trial through appeal.

18. Any waiver by Executive or Noven of a breach of any provision of this Separation Agreement
shall not be construed to be a waiver of any other breach of any provision of this Separation
Agreement. The failure of Executive or Noven to insist upon strict adherence to any term of this
Separation Agreement shall not constitute a waiver by such party to require at some subsequent time
strict adherence to such term. To be effective, any waiver must be in writing and signed by the
waiving party.

19. Neither this Separation Agreement, nor anything contained herein, shall be construed as an
admission or concession by Noven or by Executive of any liability, unlawful conduct, or wrongdoing
whatsoever.

1.

20. Executive may not assign any rights and/or benefits due and/or owing under this Agreement
unless Noven agrees to such assignment in writing. This Separation Agreement shall be binding upon
the personal representative, heirs, and permitted assigns of Executive. This Separation Agreement
may be assigned by Noven and shall inure to the benefit of and be enforceable by any successors and
assigns of Noven.

21. This Separation Agreement contains the complete, full, and exclusive understanding of
Executive and Noven and supersedes any and all other oral or written agreements between them;
provided however, that nothing herein shall adversely effect Noven’s existing
indemnification obligations owed to Executive under the Indemnity Agreement made and entered into
as of March 26, 1999, by and between Noven Pharmaceuticals, Inc., and Robert C. Strauss.
Any amendments to this Separation Agreement shall be effective and binding on Executive and
Noven only if any such amendments are in writing and signed by both parties.

22. If any provision of this Separation Agreement is invalid, illegal or unenforceable, except
for the release/waiver provisions in Section 7 or the covenants as provided in Sections 12 and 14,
it shall not affect the other provisions of this Separation Agreement, which shall remain in
effect. This Separation Agreement shall be construed in all respects as if such invalid or
unenforceable provision was omitted.

23. This Separation Agreement is governed by the laws of the State of Florida, and venue of
any action brought under this Separation Agreement shall be exclusively in Miami-Dade County,
Florida. Each of the parties to this Separation Agreement: (a) consents to the personal
jurisdiction of all Florida courts located in Miami-Dade County, Florida, and the federal court for
the Southern District of Florida in the event any dispute arises out of this Separation Agreement;
and (b) agrees that he or it will not attempt to deny or defeat such personal jurisdiction by
motion or other request for leave from any such court. Each of the parties further agrees that he
or it will not assert any claim of inconvenient forum. Any trial/hearing/proceeding under this
Separation Agreement shall be heard by a JUDGE WITHOUT A JURY.

24. Executive has up to 21 days after receiving this Separation Agreement to decide whether to
sign it. Executive should take as much of the 21 days as the Executive needs to in order to
properly evaluate the release/waiver and other provisions contained in this Separation Agreement.
Any changes of whatever kind which may be made after the Separation Agreement is initially provided
to Executive will not restart the running of the 21 day period. Executive is advised to consult
with an attorney prior to signing this Separation Agreement.

25. Executive may revoke this Separation Agreement by providing written notice of revocation
to: Jeff Mihm, Vice President and General Counsel, Noven Pharmaceuticals, Inc., 11960 SW
144th Street, Miami, Florida 33186, to be received not later than the end of the seventh day
after Executive signs this Separation Agreement. If there is no timely revocation, the Separation
Agreement shall become effective and enforceable.

1

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

BOTH PARTIES, HAVING HAD A FULL OPPORTUNITY TO REVIEW THE FOREGOING, AND BOTH PARTIES, BEING
IN COMPLETE AND FULL AGREEMENT AS TO THE TERMS OF THIS SEPARATION AGREEMENT, HAVE VOLUNTARILY
SIGNED THIS AGREEMENT.

	 	 	 
	ROBERT C. STRAUSS	 	NOVEN PHARMACEUTICALS, INC.
	/s/ Robert C. Strauss

	 	/s/ Jeff Mihm

Print Name: Jeff Mihm,

in his/her capacity as authorized representative

of Noven Pharmaceuticals, Inc.

Title: Vice President, General Counsel and Corporate Secretary

	 	 	 
	1/2/2008

Date

	 	1/2/2008

Date

2EX-10.2

RESTRICTED STOCK UNIT AGREEMENT

THIS AGREEMENT made as of the 10th day of January, 2008, between Noven Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and Robert C. Strauss. (“Grantee”).

1. Award.

(a) Shares. Pursuant to the Noven Pharmaceuticals, Inc. 1999 Long-Term Incentive Plan
(the “Plan”), the Company hereby grants to the Grantee the right to receive 50,000 shares (the
“Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Restricted Stock
Units”). The Shares shall be issued to the Grantee upon the satisfaction of the terms and
conditions set forth herein on January 10, 2010.

(b) Plan Incorporated. Grantee acknowledges receipt of a copy of the Plan, and agrees
that this award of Restricted Stock Units shall be subject to all of the terms and conditions set
forth in the Plan, including future amendments thereto, if any, pursuant to the terms thereof,
which Plan is incorporated herein by reference as a part of this Agreement.

2. Restricted Stock Units. Grantee hereby accepts the Restricted Stock Units and
agrees as follows:

(a) Forfeiture Restrictions. The Restricted Stock Units and the right to receive the
Shares may not be sold, assigned, pledged, exchanged, hypothecated or otherwise transferred,
encumbered or disposed of. The Grantee shall forfeit the Restricted Stock Units and the right to
receive the Shares if the Grantee violates any of the provisions contained in Section 12 or 14 of
the Separation Agreement between the Company and the Grantee dated January 2, 2008. The
prohibition against transfer and the risk of forfeiture described in this paragraph are herein
referred to as “Forfeiture Restrictions.”

(b) Certificates. A certificate evidencing the Shares shall be issued by the Company
in Grantee’s name no later than ten (10) business days after January 10, 2010, provided that
Forfeiture Restrictions have lapsed and not been violated. Shares. Notwithstanding any other
provisions of this Agreement, the issuance or delivery of the Shares may be postponed for such
period as may be required to comply with applicable requirements of any national securities
exchange or any requirements under any law or regulation applicable to the issuance or delivery of
such shares. The Company shall not be obligated to issue or deliver the Shares if the issuance or
delivery thereof shall constitute a violation of any provision of any law or of any regulation of
any governmental authority or any national securities exchange.

3. Withholding. To the extent that the receipt of the Restricted Stock Units, the
Shares, or the lapse of any Forfeiture Restrictions results in income to Grantee for federal or
state income tax purposes, Grantee shall deliver to the Company at the time of such receipt or
lapse, as the case may be, such amount of money as the Company may require to meet its withholding
obligation under applicable tax laws or regulations, and, if Grantee fails to do so, the Company,
may in its sole discretion, (i) cause Grantee’s right to receive the Shares as forfeited or (ii)
withhold from any cash or stock remuneration then or thereafter payable to Grantee any tax required
to be withheld by reason of such resulting compensation income.

4. Status as a Shareholder. Until the Shares are issued, the Grantee shall have no
rights as a shareholder, including the right to vote the Shares and receive all dividends and other
distributions paid or made with respect thereto.

5. Status of Shares. Grantee agrees that the Shares will not be sold or otherwise
disposed of in any manner which would constitute a violation of any applicable federal or state
securities laws. Grantee also agrees (i) that the certificates representing the Shares may bear
such legend or legends as the Company deems appropriate in order to assure compliance with
applicable securities laws, (ii) that the Company may refuse to register the transfer of the Shares
on the stock transfer records of the Company if such proposed transfer would be in the opinion of
counsel satisfactory to the Company constitute a violation of any applicable securities law and
(iii) that the Company may give related instructions to its transfer agent, if any, to stop
registration of the transfer of the Shares.

6. Committee’s Powers. No provision contained in this Agreement shall in any way
terminate, modify or alter, or be construed or interpreted as terminating, modifying or altering
any of the powers, rights or authority vested in the Committee or, to the extent delegated, in its
delegate pursuant to the terms of the Plan or resolutions adopted in furtherance of the Plan,
including, without limitation, the right to make certain determinations and elections with respect
to the Restricted Stock Units or the Shares.

7. Binding Effect. This Agreement shall be binding upon and inure to the benefit of
any successors to the Company and all persons lawfully claiming under Grantee.

8. Governing Law. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of Florida.

[SIGNATURES ON FOLLOWING PAGE]

1

IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by an officer
thereunto duly authorized, and Grantee has executed this Agreement, all as of the date first above
written.

NOVEN PHARMACEUTICALS, INC.

By: /s/ Jeff Mihm

Name: Jeff Mihm

Title: Vice President, General Counsel and Corporate Secretary

GRANTEE

/s/ Robert C. Strauss

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]